Glucagon testing and BMI: why the GH cutoff matters

A cutoff can change who receives a diagnosis

A glucagon stimulation test can contribute to adult growth-hormone-deficiency assessment, but its threshold is not a universal number that can be read without context. Research in heavier adults and comparisons of glucagon protocols have shown why an overly broad cutoff can classify some GH-sufficient people as deficient. ^{[1] [2]} This matters when an adult is considering a long-term hormone-related treatment after one low result. The useful question is not whether the laboratory value looks low in isolation. It is whether the selected test, method and threshold were appropriate for the person’s clinical circumstances and the question the specialist is trying to answer.

Body size was a reason to revisit older thresholds

Dichtel and colleagues investigated overweight or obese adults with pituitary disorders alongside controls. Their work showed that a 3 ng/mL glucagon-test threshold could classify a substantial proportion of healthy heavier controls as deficient, supporting a lower threshold in the studied setting. ^[1] That does not mean weight makes a result irrelevant or that an individual should choose their own correction. It means a number cannot be interpreted fairly when the protocol and relevant population are omitted. A clinic offering treatment should be able to explain those details rather than presenting a low response as self-evident proof of a need for ongoing therapy.

A randomized protocol comparison included forty-two people

Hamrahian and colleagues studied twenty-eight patients with hypothalamic-pituitary disease and fourteen matched controls. The patients were split between those with one or two additional pituitary deficits and those with at least three. Participants underwent an insulin tolerance test, fixed-dose glucagon and weight-based glucagon in random order. The fixed regimen was 1 mg, or 1.5 mg above ninety kilograms; the weight-based regimen was 0.03 mg/kg. ^[2] These are supervised testing procedures, not instructions for home use. The study compared diagnostic methods, so its findings should not be confused with a trial of chronic glucagon treatment or a peptide wellness program.

The two glucagon regimens did not share one best cutoff

In that small comparison, the best GH cutoff was 1 ng/mL for fixed-dose glucagon, with 92 percent sensitivity and 100 percent specificity, versus 2 ng/mL for the weight-based test, with 96 percent sensitivity and 100 percent specificity. ^[2] The point is not to choose the smaller or larger number as universally correct. It is that protocol changes can alter the interpretation. The percentages also come from a limited, selected diagnostic population. They should not be read as a promise of perfect classification in every clinic, every body-size group or every person with fatigue and an otherwise unclear endocrine history. A small matched-control design is useful for detecting protocol differences, but its estimates need external validation. In particular, perfect specificity within fourteen selected controls should not be mistaken for an assurance that false-positive results are impossible in ordinary practice.

Clinical likelihood remains part of the decision

The AACE–ACE guideline incorporates BMI and pretest likelihood into glucagon-test interpretation, rather than treating every person with the same single threshold. ^[3] That is an important safeguard against turning a nonspecific symptom into a definitive hormonal diagnosis. A history of pituitary disease, other hormone deficits and the reason for evaluation can change the meaning of the same response. A patient does not need to become an expert in diagnostic statistics to ask a useful question: which cutoff applies to this protocol and why does it fit this case? A clear answer should connect the laboratory result with the clinical history.

The same need for context applies to interpreting IGF-1 in context.

The procedure also has a safety burden

In the randomized protocol study, nausea was the most common side effect, and one participant had a seizure during the fixed-dose test. ^[2] That finding should remain attached to the study and should not become an assumed personal risk estimate. It does illustrate why the test belongs in a supervised clinical setting. The testing team should review relevant conditions and medicines and provide instructions about preparation and observation. The appeal of an alternative to insulin-induced hypoglycemia does not mean glucagon testing is a casual screening tool or that every person considering hormone optimization needs to undergo it.

A low result does not identify the treatment

A test can support a diagnosis without establishing that every growth-hormone-related therapy is interchangeable. Compounded sermorelin, direct GH replacement and other secretagogues are different interventions. The diagnostic studies discussed here did not compare their long-term benefits in the tested population. If a treatment is proposed after an abnormal response, the clinician should explain the diagnosis, appropriate management options and evidence for the selected preparation. This preserves the value of testing rather than allowing it to become a generic sales justification. The question changes from can a laboratory response be elicited to what management offers a worthwhile benefit for this person.

How to use the result constructively

Keep the full test report, including protocol, timing, assay and reference interpretation, and review it with the clinician who knows the clinical history. Do not independently reinterpret a borderline result from a table found online or change treatment because another website uses a different number. If a service is proposing a recurring program, request a clear explanation of how the diagnosis was reached and why that program follows. The key conclusion is practical: BMI and glucagon-test protocol can matter enough to change classification. A careful interpretation is therefore part of the treatment decision, not a minor technical detail to be skipped once a low number appears.

For a clinic-model comparison after the clinical question is clear, read our Low T Center review.